Key Points
- Adaptive Biotechnologies COO Julie Rubinstein sold 19,060 shares on April 1 at an average price of $14.45 (≈$275,417), executed under a pre-arranged Rule 10b5-1 trading plan, leaving her with 451,540 shares (~$6.52M) — a 4.05% reduction in her holdings.
- She completed a string of large insider sales in March totaling about 368,226 shares, including a 141,583-share sale on March 11, indicating substantial insider disposition during the month.
- Adaptive trades near $14.81 with a one-year range of $6.68–$20.76; the company reported 51% revenue growth and an EPS beat last quarter, and analysts rate the stock a “Moderate Buy” with an average target of $18.25.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $14.45, for a total transaction of $275,417.00. Following the completion of the transaction, the chief operating officer owned 451,540 shares in the company, valued at approximately $6,524,753. This trade represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total transaction of $263,599.80.
- On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total transaction of $254,832.20.
- On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total transaction of $251,210.80.
- On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total transaction of $255,594.60.
- On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total transaction of $1,881,638.07.
- On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total transaction of $247,017.60.
- On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total value of $457,617.39.
- On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total value of $285,672.80.
- On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.
- On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total value of $495,056.00.
Adaptive Biotechnologies Stock Performance
NASDAQ:ADPT opened at $14.81 on Friday. Adaptive Biotechnologies Corporation has a 1 year low of $6.68 and a 1 year high of $20.76. The stock has a fifty day moving average price of $15.53 and a two-hundred day moving average price of $15.92. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -37.02 and a beta of 2.29.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. The company had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business's revenue was up 51.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.23) EPS. On average, analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.
Institutional Investors Weigh In On Adaptive Biotechnologies
Hedge funds and other institutional investors have recently modified their holdings of the company. Allianz Asset Management GmbH boosted its position in Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company's stock worth $4,814,000 after acquiring an additional 242,474 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Adaptive Biotechnologies by 82.5% during the third quarter. SG Americas Securities LLC now owns 68,113 shares of the company's stock worth $1,019,000 after purchasing an additional 30,785 shares during the last quarter. Affinity Wealth Management LLC purchased a new stake in shares of Adaptive Biotechnologies in the third quarter valued at $4,541,000. Aristotle Atlantic Partners LLC increased its stake in Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company's stock valued at $46,776,000 after purchasing an additional 247,402 shares during the last quarter. Finally, Huntleigh Advisors Inc. acquired a new position in Adaptive Biotechnologies in the third quarter valued at $1,227,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on ADPT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen lowered Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Guggenheim upped their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. BTIG Research boosted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, February 6th. Finally, TD Cowen reissued a "buy" rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $18.25.
View Our Latest Stock Analysis on ADPT
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
